Track the Chordia Therapeutics株式会社 stock price and the full insider trade history of the company, a listed issuer based in Japan. Shares are quoted on JP JP, under the authority of EDINET (Japan FSA). Market capitalisation: €122.7bn. The latest transaction was filed on 22 May 2026 (Holding update). Among the most active insiders: SBI Investment Co., Ltd.. Every trade is free.
29
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
24Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 9,553 of 25,484 companies
58.3
score / 100
Value
54
Quality
63
FCF yld4.5%
Earn yld5.3%
EV/EBITDA16.8x
ROE4.6%
Gross mgn45%
Net mgn30%
Debt/EBITDA1.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Chordia Therapeutics is a company listed on the XTKS market, specializing in the development of innovative therapies. It focuses on research and commercialization of treatments for various diseases.